News Image

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Provided By GlobeNewswire

Last update: Mar 3, 2025

Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life

APG279 (APG777 + APG990) Phase 1b head-to-head study vs. DUPIXENT supported by successful completion of preclinical combination toxicology studies and positive APG990 interim Phase 1 results; trial planned to initiate this year with readout expected in second half of 2026

Read more at globenewswire.com

APOGEE THERAPEUTICS INC

NASDAQ:APGE (6/9/2025, 8:09:28 PM)

After market: 40.13 0 (0%)

40.13

-0.85 (-2.07%)



Find more stocks in the Stock Screener

Follow ChartMill for more